MedTrace Logo

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

NCT01468181 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 394

Last updated 2015-01-29

Study results available
· View outcomes & findings →

Summary

This was a 52-week, multicenter, non-randomized, open-label, Phase 3 long-term safety study in participants with type 2 diabetes mellitus who have inadequate glycemic control with monotherapy of oral antihyperglycemic medication (OAM).

Conditions

Interventions

DRUG

LY2189265

DRUG

Sulfonylureas (SU)

SU is a pre-study prescribed dose and is not being provided as part of the trial.

DRUG

Biguanides (BG)

Biguanides is a pre-study prescribed dose and is not being provided as part of the trial.

DRUG

alpha-glucosidase inhibitor (a-GI)

a-GI is a pre-study prescribed dose and is not being provided as part of the trial.

DRUG

Thiazolidinedione (TZD)

TZD is a pre-study prescribed dose and is not being provided as part of the trial.

DRUG

Glinides

Glinides is a pre-study prescribed dose and is not being provided as part of the trial.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM-5PM Eastern time (UTC/GMT - 5, hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01468181 on ClinicalTrials.gov